Lumito AB Quarterly Report (1 October to 31 December) 2019
Financial overview of the fourth quarter, 1 October – 31 December 2019 Result after taxes amounted to kSEK -2,545 (-2,148). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -3,145 (-2,148). Financial overview of the year as a whole, 1 January – 31 December […]
Status update regarding the completion of Lumito’s first product
The development of Lumito’s first product (instrument + staining reagent) in digital tissue diagnostics, for analyzing tissue sections stained with the company’s nano-based staining reagents, is entering its final stage prior to launch. The development of the actual instrument is proceeding according to plan, and the first instruments, which are intended for customer validation at […]
First exercise window for Lumito warrants closes
On 29 November, Lumito AB (publ) (“Lumito”) ended the first exercise period for the Series 2 TO2 subscription warrant. The exercise rate was 72.3 percent, at an exercise price of SEK 1.45 per share. In total, 11,179,281 new shares have been subscribed during the now concluded first exercise period. Lumito is thus provided approximately MSEK […]
Lumito AB is provided approximately MSEK 38.7 in cash through an over-subscribed rights issue and a decided over-allotment
Lumito AB (publ) announces today that the Company's new share issue amounting to approximately MSEK 35.7 has been subscribed to a total of 155 percent. The commitments from the guarantee consortium do therefore not have to be utilized. In addition, an over-allotment issue of MSEK 3.0 has been decided. An extraordinary general meeting of Lumito […]
